Compare Enveric Biosciences Inc (ENVB) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.5 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 5757.4× Enveric Biosciences Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 110 Days on average.
| ENVB | TTWO | |
|---|---|---|
Market Cap | $6.80M | $39.15B |
Volume | 64,867 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $10.80 | $262.29 |
52-Week Low | $1.27 | $189.69 |
Typical Hold Time | 14 Days | 110 Days |
Enterprise Value | -$1.49M | $40.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Take-Two Interactive trades at $204.01, up 0.73% with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63B but faces profitability challenges with a -79.51% net margin. Analyst consensus remains strongly bullish with a $292.30 price target, supported by GTA VI's confirmed November 2026 launch. Cash flow improved significantly to $457M in 2025, though debt-to-asset ratio rose to 39.87%.
The stock presents a high-risk, high-reward opportunity with GTA VI as the primary catalyst. While current fundamentals show losses, the 79% buy rating reflects optimism for the upcoming release. Key risks include execution on the major title launch, competitive pressure, and the company's elevated debt levels. Near-term performance will likely hinge on pre-launch momentum and Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
